The PASS PULL EV-ICD Study is a prospective, multi-center, single-arm study without concurrent or historical controls. This initial concept feasibility study is primarily intended to demonstrate that the EV-ICD Lead can be safely positioned within the anterior mediastinum as intended using the AtaCor delivery system. The study will secondarily characterize the ability for the EV-ICD Lead to facilitate VF sensing and defibrillation.
The primary objective of the study is to demonstrate that the AtaCor EV-ICD Lead can be safely positioned within the anterior mediastinum as intended using the EV-ICD Dilator and EV-ICD Delivery Tool. The study will secondarily characterize the ability for the EV-ICD Lead to facilitate VF sensing and defibrillation. Up to 3 Investigational Sites will participate with up to 65 subjects enrolled in the study. Patients undergoing de novo or replacement ICD procedure will be eligible for participation. Study participation requires acute evaluation of the EV-ICD Lead during the index procedure. Echocardiography will be used to evaluate any new or worsening pericardial effusions. A follow-up visit will occur 7-10 days post-removal via phone, video call, or in-person. Participation will end after completion of the 7-10 days post-removal visit. The Study is expected to last up to 3 months for enrollment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
18
Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
Sanatorio Italiano
Asunción, Paraguay
Incidence of SADEs
Incidence of Serious Adverse Device Effects (SADEs)
Time frame: Up to 10 days post-procedure
Rate of Insertion Success
Defined as the ability to deploy the lead in a position within the mediastinum that is suitable for defibrillation testing and does not result in one (1) or more SADEs
Time frame: Procedure
Functionality - Lowest Defibrillation Conversion Energy
Lowest Defibrillation Conversion Energy (J)
Time frame: Procedure
Observational: Incidence of ADEs
Incidence of Adverse Device Effects (ADEs), Overall and Individual
Time frame: Up to 10 days post-procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.